Opinions expressed by Entrepreneur contributors are their own.
A new CBD pill designed to manage pain and inflammation proved effective in a recent trial conducted by New York University involving patients who underwent arthroscopic rotator cuff repair.
The study found that shoulder surgery patients experienced significantly less pain than patients in a control group who received a placebo. Patients who received 50mg of CBD also felt better than those who received 25mg.
The pill, called Oravexx, was developed by New Jersey-based company Orcosa. Dr. Michael J. Alaia led the study at NYU Langone Health and Baptist Health/Jacksonville Orthopaedic Institute.
“We are grateful for the patients and investigators whose participation in this study evaluating CBD as a pain management therapy that may lead to improved treatment options for patients,” said Mark Ridall, Founder and Chief Executive Officer of Orcosa.
What is Oravexx?
Many studies focus on Pain management involving CBD and THC (or a cocktail of the two). Millions of people experience difficulty managing pain, and poorly managed pain leads to further health problems, including negative physical and psychological issues. For postoperative patients, it also can lead to readmission to the hospital.
Orcosa developed Oravexx to address pain management using chemical compounds found in CBD, a naturally occurring cannabis ingredient that does not get users high. It’s a non-addictive type of pain management where the company focuses its product development.
Referencing the current opioid epidemic in the U.S., the Orcosa website noted that “it is critically important to patients, doctors, and regulators, including the U.S. Food and Drug Administration (FDA), that alternative pain management therapies be developed.”
Findings from the Oravexx study
Ninety-nine patients participated in the study. Researchers split the patients into groups that received doses containing 50mg of CBD, 25 mg of CBD, and no CBD for a control group.
Alaia reported the findings at the American Academy of Orthopaedic Surgeons annual meeting in Chicago. Highlights included the following.
On the first day after surgery, patients receiving the new treatment experienced 23% less pain on average than those who received a placebo.
On the first and second days after surgery, patients who took Oravexx reported 22 percent to 25 percent greater satisfaction with pain control than those who received placebo.
The patients who took 50 mg of CBD reported lower pain and higher satisfaction with pain control than those who took the placebo or 25 mg of CBD.
During the study, those who took Oravexx consistnetly outperformed the control group. They also reported no side effects from CBD use.
The study follows past studies that have reported patients experiencing better pain management when using CBD. For example, a Canadian study showed patients experienced better sleep and improved pain management using both CBD and THC. A Harvard University found patients experienced better moods and less pain using a combination of THC and CBD.